Announcements Trials

Browse Landscape

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 26 Rectal Neoplasms 6 Colonic Neoplasms 6 Neoplasm Metastasis 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Advanced Solid Tumors 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Gallbladder Neoplasms 2 Advanced Solid Tumors (Excluding Breast Cancer) 2 Urologic Diseases 1 Solid Tumor Cancer 1 Renal Insufficiency 1 Refractory Solid Tumors 1 Pretreated Metastatic Colorectal Cancer 1 Neoplasms 1 Liver Neoplasms 1 Liver Diseases 1 Kidney Neoplasms 1 Kidney Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Gastric Adenocarcinoma 1 Digestive System Diseases 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma 1 Breast Neoplasms 1 Bile Duct Neoplasms 1 Advanced or Metastatic Solid Tumors 1

Interventions

Trastuzumab 350 Paclitaxel 334 Cyclophosphamide 315 Docetaxel 291 Capecitabine 181 Doxorubicin 180 Letrozole 165 Tamoxifen 145 Bevacizumab 124 Fulvestrant 118 Carboplatin 118 exemestane 111 Lapatinib 111 Anastrozole 111 Radiotherapy 105 Epirubicin 104 Gemcitabine 97 palbociclib 83 Exercise 78 Vinorelbine 77 Fluorouracil 77 Surveys and Questionnaires 71 pertuzumab 67 Filgrastim 64 Albumin-Bound Paclitaxel 64 eribulin 55 Magnetic Resonance Spectroscopy 55 Everolimus 52 Blood Specimen Collection 51 Zoledronic Acid 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Neoplasms × trifluridine tipiracil drug combination × Clear all

NCT04489173 2026-05-22

TIBET

Borstkanker Onderzoek Groep

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡